Gilead Sciences’ Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and Chief Scientific Officer, effective at the end of April 2018. He will remain with the company through July. John McHutchison, MD, currently Executive Vice President, Clinical Research, will be appointed Chief Scientific Officer and assume responsibility for the company’s research and development organization. Also effective in April, Andrew Cheng, MD, PhD, Executive Vice President, Clinical Research & Development Operations, will be appointed Chief Medical Officer. Both Dr. McHutchison and Dr. Cheng will report to John Milligan, PhD, Gilead’s President and Chief Executive Officer.
Dr. Bischofberger joined Gilead in 1990 and has served as Executive Vice President since 2000 and Chief Scientific Officer since 2007. In nearly 30 years with the company, Dr. Bischofberger has overseen the development of more than 25 compounds that are available today for a range of serious medical conditions.
“There are few people across the entire biopharmaceutical industry who have had the kind of impact Norbert has had on transforming the treatment of serious diseases, or who have demonstrated his depth of understanding of and caring for the needs of people living with those diseases,” said Dr. Milligan. “I have worked alongside Norbert for nearly three decades, and I know I speak for the entire Gilead organization in expressing my profound thanks to him for what he has done to build this company and to change the lives of so many individuals around the world. We wish him all the best in the next phase of his professional career.”
Dr. McHutchison joined Gilead in 2010 as Senior Vice President, Liver Disease Therapeutics and was named Executive Vice President, Clinical Research in 2014. Under his leadership, Gilead has developed five medications for the treatment of chronic hepatitis B and hepatitis C that have been used by nearly 2 million people around the world.
“John is an extraordinary physician and a visionary leader,” commented Dr. Milligan. “The work he has led in the field of viral hepatitis is clear evidence of his capabilities, and we are excited to have him bring the same energy and focus to his new role. I am confident that John’s leadership and his deep clinical and scientific expertise will allow Gilead to advance the promising compounds in our pipeline and drive the kind of innovative research and development programs that have been a hallmark of our history and will help us build for the future.”
Prior to joining Gilead, Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center and Co-Director of the Duke Clinical and Translational Science Award. Prior to his positions at Duke, Dr. McHutchison spent nearly 10 years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. Dr. McHutchison received bachelor of medicine and bachelor of surgery degrees from the University of Melbourne, Australia, and completed his residency in internal medicine and a fellowship in gastroenterology at the Royal Melbourne Hospital. He is also a member of the Royal Australasian College of Physicians.
Dr. Cheng joined Gilead in 1999 to lead company’s development-stage programs in HIV/AIDS. He received additional responsibility for the company’s Development Operations organization in 2009 and was named Executive Vice President in 2015. Under Dr. Cheng’s leadership, Gilead has developed and received regulatory approval for medicines that have transformed care for millions of people around the world with HIV, viral hepatitis and other serious illnesses.
In his new role as Chief Medical Officer, Dr. Cheng will retain leadership of the company’s HIV clinical research program and will assume responsibility for Gilead’s Medical Affairs organization.
“Andrew has demonstrated tremendous vision and leadership over nearly two decades at Gilead, building a world-class organization that is able to advance experimental products through clinical development and regulatory approval with industry-leading speed,” noted Dr. Milligan. “Gilead will benefit from Andrew’s clinical and scientific expertise in his new role, as he assumes oversight of post-approval studies that are vital to better understanding the company’s more than 20 approved products and their potential to help a greater number of patients with life-threatening illnesses.”
Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles. He received his medical degree and PhD in Cellular and Molecular Biology from Columbia University and his undergraduate degree from the Johns Hopkins University.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Amy Flood, 650-522-5643
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
NEC and Samsung Announce 5G Partnership Agreement24.10.2018 04:00 | Tiedote
NEC Corporation (NEC) (TOKYO: 6701) and Samsung Electronics Co., Ltd., today announced a partnership of joint effort to strengthen their next generation business portfolio including 5G. The partnership brings together the best-in-class technology and expertise in 5G, merging NEC and Samsung’s leadership in 5G and IT solutions. It also provides mobile carriers with flexible 5G solutions that are localized for each region with customized services to meet mobile carriers’ demands efficiently. Since 5G will enable unprecedented services and business models, it is inevitable for mobile carriers to demand customized solutions and flexible network architecture. Through this partnership, both companies will satisfy these growing demands effectively by joining the best forces and capabilities from each company. "5G development based on standardization will help to accelerate business transformation throughout global markets,” said Atsuo Kawamura, Executive Vice President and President of the Ne
Coronation Fund Managers Goes Live with SmartStream’s Corporate Actions Solution24.10.2018 02:01 | Tiedote
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced that Coronation Fund Managers, one of the largest independent fund managers in South Africa, has gone live with TLM Corporate Actions OnDemand – automating the complete corporate actions lifecycle. Llewellyn Smith, COO at Coronation states: “We continue to make investments in our business, specifically in technology that enhances our clients’ service experience, and which allows us to achieve greater operational efficiencies. Through SmartStream’s tailored solution, we achieve automation of our corporate actions operational processes. Given that this project ran in parallel with a number of strategic initiatives, its successful implementation was essential. We value SmartStream’s corporate actions expertise which guided us through the procedure in less than four months”. Coronation is using the TLM® Corporate Actions OnDemand solution to process mandatory and voluntary ev
EASA Approves AerTrak ADS-B Out System for Boeing 737 NG Series Aircraft24.10.2018 00:47 | Tiedote
AerSale ®, a global supplier of mid-life aircraft, engines, used serviceable material, and MRO services, announced today that the European Aviation Safety Agency (EASA) has approved the company’s AerTrak™ ADS-B Out system on Boeing 737 NG series aircraft (10065422). Earlier this year, the Federal Aviation Administration (FAA) approved AerTrak for Boeing 737 NG series aircraft (ST04009NY) and Boeing 757-200 series aircraft (ST04011NY) to comply with the FAA’s Automatic Dependent Surveillance-Broadcast (ADS-B) Operations rule. The Boeing 757-200 series aircraft Supplemental Type Certificate (STC) is now pending EASA and National Civil Aviation Agency of Brazil (ANAC) validation. “With this validation, we demonstrate our commitment to our European customer base,” said Iso Nezaj, Chief Technical Officer at AerSale. “Operators can now choose a fully-compliant ADS-B Out system visible to all—with no certification fees. We’re working to expand AerTrak to cover additional aircraft types and lo
Greene Tweed Receives Patent for Rapid Gas Decompression-Resistant Fluoroelastomers and Molded Articles24.10.2018 00:00 | Tiedote
The U.S. Patent Office has awarded Greene Tweed Patent Number 10,011,690 for Rapid Gas Decompression-Resistant Fluoroelastomer Compositions and Molded Articles. The innovative elastomer technology was developed by a team that included inventor Ron Campbell, PhD, Principal Scientist and Technology Leader for Elastomers in Greene Tweed’s Advanced Technology Group, to provide a competitive advantage in the Energy market and expand technology protected under a previous patent. Rapid gas decompression (RGD) often occurs when high-pressure gas molecules migrate into an elastomer at a compressed state. When the pressure surrounding the elastomer is suddenly released, the compressed gas inside the elastomer tries to expand and exit the elastomer, thus causing RGD (also known as explosive decompression). Most elastomers experience severe blistering or cracking when the force of these expanding gases overcome the strength of the surrounding material; however, materials engineered to withstand RG
Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains23.10.2018 21:00 | Tiedote
Scientists at Morinaga Milk Industry Co., Ltd. (TOKYO:2264) have long theorized that Human-Residential Bifidobacteria (HRB) are superior to non-Human-Residential Bifidobacteria (non-HRB) in promoting good health outcomes. The results of a new study strengthen the evidence for this theory, showing that infant-type HRB may be able to break down incompletely digested peptides in the infants’ gastrointestinal systems and thus contribute to their overall health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005015/en/ Fig 1. Food-derived opioid peptides are potential risk factors for human health (Graphic: Business Wire) Human-Residential Bifidobacteria for Humans Morinaga Milk has been conducting research on bifidobacteria for many years, and studies over the past decades have shown that bifidobacteria play a vital role in various aspects of human health. There are two major groups of bifidobacteria: Human-Residential Bif
myPOS Founder Christo Georgiev Announces Two Upcoming myPOS Stores in Barcelona and Paris23.10.2018 19:22 | Tiedote
Christo Georgiev, fintech entrepreneur and founder of myPOS, has confirmed his intention to open two new flagship stores in major European cities by the end of the year. The opening is part of an initiative to bring the product closer to potential customers, giving them a hands-on experience and a live demonstration of what myPOS has to offer. The two new stores will be opened in Barcelona, Spain and Paris, France – two of the most important markets for myPOS. “Our Spanish and French customers have always placed a tremendous amount of trust in us, and we in turn have worked hard to justify it,” Georgiev says. “Opening physical locations in Barcelona and Paris is an extension of that relationship. It’s important to test a product with your own hands before you choose to trust it, and if that’s true for TVs and phones why can’t it apply to POS terminals?” The Barcelona store will open as soon as November, followed shortly by the Paris one before the end of the year. myPOS has already ope
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme